TNGX Tango Therapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of tangotx.com (TNGX)

The enterprise value assessment via EV/Sales demonstrates the asset's dynamics, where the 0.00 mark serves as a key metric. Tango Therapeutics (TNGX) is implementing robots for accelerated molecule screening. Manufacturing processes have been outsourced to external plants to ensure stability. Meanwhile, the company adheres to ESG standards by optimizing biomaterial recycling and reagent logistics.

Company Value to Revenue: Tango Therapeutics Inc (TNGX) for 11/23/2025 - 11/20/2026

tangotx.com - analytical breakdowns and key metrics (TNGX)

- share price and consensus valuation forecast:
Initial company analysis:Tango Therapeutics TNGX
Product sample of Tango Therapeutics

Tango Therapeutics (TNGX) develops advanced oncology drugs currently in clinical trials. This indicator excludes the impact of leverage, measuring the enterprise value through the lens of generated revenue. By analyzing the enterprise value-to-revenue ratio, one can identify unjustified price spikes or undervalued assets. For a company with an emerging product life cycle, this serves as a critical filter against overpayment. Extreme values of this metric signal either inflated expectations or the risk of capital stagnation.

Competitor analysis for Tango Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP